Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers.
Patrys' says preclinical data supports synthetic lethality mechanism
March 15, 2023 Australian Biotech
Latest Video
New Stories
-
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast -
Another day, another confusing response to the threat of US tariffs
July 17, 2025 - - Latest News -
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News